Merck's earnings call highlights strong growth across key product lines, particularly KEYTRUDA and GARDASIL.  Management expresses confidence in continued strong growth in 2024, driven by existing products and upcoming launches like sotatercept and V116.  The call emphasizes ongoing investment in research and development and a focus on science-led initiatives, hinting at further expansion in the business.
[1]
